Inventor · disambiguated record
Sabine Zollner
Also filed as: ZOLLNER SABINE
9 granted patents·1 pending application·29 citations·filing 2012–2020
84Inventor score
Top patents by PatentIndex Score
10 records- 0192US9956269B2Method for improving the stability of purified factor VIII after reconstitutionCSL LTD·Filed 2016·Granted May 1, 2018·12 cites·18 claims
- 0289US10881717B2Method for improving the stability of purified Factor VIII after reconstitutionCSL LTD·Filed 2019·Granted Jan 5, 2021·3 cites·24 claims
- 0387US10537616B2Method for improving the stability of purified factor VIII after reconstitutionCSL LTD·Filed 2018·Granted Jan 21, 2020·5 cites·18 claims
- 0487US9394353B2Method for improving the stability of purified factor VIII after reconstitutionCSL LTD·Filed 2012·Granted Jul 19, 2016·9 cites·7 claims
- 0574US11510968B2Method for improving the stability of purified Factor VIII after reconstitutionCSL LTD·Filed 2020·Granted Nov 29, 2022·0 cites·24 claims
- 0653US9707269B2Sugar compositions for treating hemophilia A and/or von Willebrand diseaseCSL BEHRING GMBH·Filed 2013·Granted Jul 18, 2017·0 cites·10 claims
- 0752US9511123B2Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIIICSL BEHRING GMBH·Filed 2012·Granted Dec 6, 2016·0 cites·5 claims
- 0851US10232015B2Sugar compositions for treating hemophilia A and/or Von Willebrand diseaseCSL BEHRING GMBH·Filed 2017·Granted Mar 19, 2019·0 cites·20 claims
- 0949US9393289B2Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIIICSL BEHRING GMBH·Filed 2012·Granted Jul 19, 2016·0 cites·18 claims
- 1030US2017042981A1Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens thereforCSL LTD·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sabine Zollner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →